Palmitoylethanolamide reduces pain-related behaviors and restores glutamatergic synapses homeostasis in the medial prefrontal cortex of neuropathic mice

Molecular Brain

Volumn 8, Issue 1, 2015, Pages

  Guida, F ^a   Luongo, L ^a   Marmo, F ^b   Romano, R ^a   Iannotta, M ^a   Napolitano, F ^c   Belardo, C ^a   Marabese, I ^a   D'Aniello, A ^e   De Gregorio, D ^a   Rossi, F ^a   Piscitelli, F ^d   Lattanzi, R ^f   De Bartolomeis, A ^b   Usiello, A ^c   Di Marzo, V ^d   De Novellis, V ^a   Maione, S ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c CEINGE BIOTECNOLOGIE AVANZATE   (Italy)

^d CNR   (Italy)

^e STAZIONE ZOOLOGICA ANTON DOHRN   (Italy)

^f SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; BRAIN DERIVED NEUROTROPHIC FACTOR RECEPTOR; BRAIN PROTEIN; N OLEOYLETHANOLAMINE; PALMIDROL; POSTSYNAPTIC PROTEIN; PROTEIN KINASE B; UNCLASSIFIED DRUG; ETHANOLAMINE DERIVATIVE; GLUTAMIC ACID; PALMITIC ACID DERIVATIVE;

ANIMAL BEHAVIOR; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN SYNAPTOSOME; COGNITIVE DEFECT; CONTROLLED STUDY; DEPRESSION; DISEASE ASSOCIATION; DRUG EFFECT; EMBRYO; EVOKED BRAIN STEM RESPONSE; GLUTAMATERGIC SYNAPSE; HOMEOSTASIS; HYPERSENSITIVITY; MALE; MEDIAL PREFRONTAL CORTEX; MICROGLIA; MICROINJECTION; MOUSE; NERVE CELL PLASTICITY; NEUROPATHIC PAIN; NONHUMAN; OBSESSIVE COMPULSIVE DISORDER; PAIN THRESHOLD; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; SCIATIC NERVE INJURY; SIGNAL TRANSDUCTION; ANIMAL; CELL CULTURE; DRUG EFFECTS; ELECTROPHYSIOLOGY; IMMOBILIZATION; METABOLISM; NERVE CELL; NEURALGIA; PATHOLOGY; PATHOPHYSIOLOGY; PREFRONTAL CORTEX; SYNAPSE; TAIL;

ANIMALIA; MUS;

ANIMALS; BEHAVIOR, ANIMAL; BRAIN-DERIVED NEUROTROPHIC FACTOR; CELLS, CULTURED; ELECTROPHYSIOLOGICAL PHENOMENA; ETHANOLAMINES; GLUTAMIC ACID; HOMEOSTASIS; IMMOBILIZATION; MALE; MICE; MICROGLIA; MICROINJECTIONS; NEURALGIA; NEURONS; PALMITIC ACIDS; PREFRONTAL CORTEX; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, TRKB; SIGNAL TRANSDUCTION; SYNAPSES; TAIL;

EID: 84938855912     PISSN: None     EISSN: 17566606     Source Type: Journal    
DOI: 10.1186/s13041-015-0139-5     Document Type: Article

References (69)

1. Neugebauer V, Galhardo V, Maione S, Mackey SC. Forebrain pain mechanisms. Brain Res Rev. 2009;60:226-42. 76.
2. Luongo L, Guida F, Boccella S, Bellini G, Gatta L, Rossi F, et al. Palmitoylethanolamide reduces formalin-induced neuropathic-like behaviour through spinal glial/microglial phenotypical changes in mice. CNS Neurol Disord Drug Target. 2013;12(1):45-54.
3. Guida F, Luongo L, Aviello G, Palazzo E, De Chiaro M, Gatta L, et al. Salvinorin A reduces mechanical allodynia and spinal neuronal hyperexcitability induced by peripheral formalin injection. Mol Pain. 2012;8:60.
4. Guida F, Lattanzi R, Boccella S, Maftei S, Romano R, Marconi R, et al. PC1, a non-peptide PKR1-preferring antagonist, reduces pain behavior and spinal neuronal sensitization in neuropathic mice. Pharmacol Res. 2014;91:36-46.
5. Rossi F, Marabese I, De Chiaro M, Boccella S, Luongo L, Guida F, et al. Dorsal striatum metabotropic glutamate receptor 8 affects nocifensive responses and rostral ventromedial medulla cell activity in neuropathic pain conditions. J Neurophysiol. 2014;111(11):2196-209.
6. Walker AK, Kavelaars A, Heijnen CJ, Dantzer R. Neuroinflammation and comorbidity of pain and depression. Pharmacol Rev. 2013;66(1):80-101.
7. de Novellis V, Vita D, Gatta L, Luongo L, Bellini G, De Chiaro M, et al. The blockade of the transient receptor potential vanilloid type 1 and fatty acid amide hydrolase decreases symptoms and central sequelae in the medial prefrontal cortex of neuropathic rats. Mol Pain. 2011;17:7.
8. Giordano C, Cristino L, Luongo L, Siniscalco D, Petrosino S, Piscitelli F, et al. TRPV1-dependent and -independent alterations in the limbic cortex of neuropathic mice: impact on glial caspases and pain perception. Cereb Cortex. 2012;22(11):2495-518.
9. Millecamps M, Centeno MV, Berra HH, Rudick CN, Lavarello S, Tkatch T, et al. D-cycloserine reduces neuropathic pain behavior through limbic NMDA-mediated circuitry. Pain. 2007;132:108-23.
10. Cao H, Cui YH, Zhao ZQ, Cao XH, Zhang YQ. Activation of extracellular signal-regulated kinase in the anterior cingulate cortex contributes to the induction of long-term potentiation in rats. Neurosci Bull. 2009;25(5):301-8.
11. Alvarado S, Tajerian M, Millecamps M, Suderman M, Stone LS, Szyf M. Peripheral nerve injury is accompanied by chronic transcriptome-wide changes in the mouse prefrontal cortex. Mol Pain. 2013;9:21.
12. Cheng KI, Wang HC, Chang LL, Wang FY, Lai CS, Chou CW, et al. Pretreatment with intrathecal amitriptyline potentiates anti-hyperalgesic effects of post-injury intra-peritoneal amitriptyline following spinal nerve ligation. BMC Neurol. 2012;12:44.
13. Burke NN, Finn DP, Roche M. Chronic administration of amitriptyline differentially alters neuropathic pain-related behaviour in the presence and absence of a depressive-like phenotype. Behav Brain Res. 2014;278:193-201.
14. Apkarian AV, Sosa Y, Sonty S, Levy RM, Harden RN, Parrish TB, et al. Chronic back pain is associated with decreased prefrontal and thalamic gray matter density. J Neurosci. 2004;24(46):10410-5.
15. Metz AE, Yau HJ, Centeno MV, Apkarian AV, Martina M. Morphological and functional reorganization of rat medial prefrontal cortex in neuropathic pain. Proc Natl Acad Sci U S A. 2009;106(7):2423-8.
16. Luongo L, de Novellis V, Gatta L, Palazzo E, Vita D, Guida F, et al. Role of metabotropic glutamate receptor 1 in the basolateral amygdala-driven prefrontal cortical deactivation in inflammatory pain in the rat. Neuropharmacol. 2012;66:317-29.
17. Guindon J, Hohmann AG. The endocannabinoid system and pain. CNS Neurol Disord Drug Targets. 2009;8(6):403-21.
18. Starowicz K, Przewlocka B. Modulation of neuropathic-pain-related behaviour by the spinal endocannabinoid/endovanilloid system. Philos Trans R Soc Lond B Biol Sci. 2012;367(1607):3286-99.
19. Luongo L, Maione S, Di Marzo V. Endocannabinoids and neuropathic pain: focus on neuron-glia and endocannabinoid-neurotrophin interactions. Eur J Neurosci. 2014;39(3):401-8.
20. Palazzo E, Marabese I, de Novellis V, Oliva P, Rossi F, Berrino L, et al. Metabotropic and NMDA glutamate receptors participate in the cannabinoid-induced antinociception. Neuropharmacology. 2001;40(3):319-26.
21. Palazzo E, Luongo L, de Novellis V, Rossi F, Marabese I, Maione S. Transient receptor potential vanilloid type 1 and pain development. Curr Opin Pharmacol. 2012;12(1):9-17.
22. Sánchez-Blázquez P, Rodríguez-Muñoz M, Garzón J. The cannabinoid receptor 1 associates with NMDA receptors to produce glutamatergic hypofunction: implications in psychosis and schizophrenia. Front Pharmacol. 2014;4:169.
23. Petrosino S, Palazzo E, de Novellis V, Bisogno T, Rossi F, Maione S, et al. Changes in spinal and supraspinal endocannabinoid levels in neuropathic rats. Neuropharmacology. 2007;52(2):415-22.
24. Miller LK, Devi LA. The highs and lows of cannabinoid receptor expression in disease: mechanisms and their therapeutic implications. Pharmacol Rev. 2011;63(3):461-70.
25. de Novellis V, Luongo L, Guida F, Cristino L, Palazzo E, Russo R, et al. Effects of intra-ventrolateral periaqueductal grey palmitoylethanolamide on thermoceptive threshold and rostral ventromedial medulla cell activity. Eur J Pharmacol. 2012;676(1-3):41-50.
26. De Filippis D, Luongo L, Cipriano M, Palazzo E, Cinelli MP, de Novellis V, et al. Palmitoylethanolamide reduces granuloma-induced hyperalgesia by modulation of mast cell activation in rats. Mol Pain. 2011;7:3.
27. Citraro R, Russo E, Scicchitano F, van Rijn CM, Cosco D, Avagliano C, et al. Antiepileptic action of N-palmitoylethanolamine through CB1 and PPAR-α receptor activation in a genetic model of absence epilepsy. Neuropharmacology. 2013;69:115-26.
28. Skaper SD, Facci L, Giusti P. Glia and mast cells as targets for palmitoylethanolamide, an anti-inflammatory and neuroprotective lipid mediator. Mol Neurobiol. 2013;48(2):340-52.
29. Di Cesare Mannelli L, D'Agostino G, Pacini A, Russo R, Zanardelli M, Ghelardini C, et al. Palmitoylethanolamide is a disease-modifying agent in peripheral neuropathy: pain relief and neuroprotection share a PPAR-alpha-mediated mechanism. Mediators Inflamm. 2013;2013:328797.
30. Decosterd I, Woolf CJ. Spared nerve injury: an animal model of persistent peripheral neuropathic pain. Pain. 2000;87(2):149-58.
31. Paxinos G, Watson C. The rat brain in Stereotaxic Coordinates. London: Academic; 1986.
32. Matias I, Di Marzo V. Endocannabinoids and the control of energy balance. Trends Endocrinol Metab. 2007;18(1):27-37. Review.
33. Pérez-Jaranay JM, Vives F. Electrophysiological study of the response of medial prefrontal cortex. Brain Res. 1991;564:97-101.
34. Floresco SB, Tse MT. Dopaminergic regulation of inhibitory and excitatory transmission in the basolateral amygdala-prefrontal cortical pathway. J Neurosci. 2007;27:2045-57.
35. Constantinidis C, Goldman-Rakic PS. Correlated discharges among putative pyramidal neurons and interneurons in the primate prefrontal cortex. J Neurophysiol. 2002;88:3487-97.
36. Laviolette SR, Grace AA. Cannabinoids potentiate emotional learning plasticity in neurons of the medial prefrontal cortex through basolateral amygdala inputs. J Neurosci. 2006;26:6458-68.
37. Simone DA, Khasabov SG, Hamamoto DT. Changes in response properties of nociceptive dorsal horn neurons in a murine model of cancer pain. Sheng Li Xue Bao. 2008;60:635-44.
38. Zhang F, Vadakkan KI, Kim SS, Wu LJ, Shan GY, Zhuo M. Selective activation of microglia in spinal cord but not higher cortical regions following nerve injury in adult mouse. Mol Pain. 2008;4:15.
39. Apkarian AV, Bushnell MC, Treede RD, Zubieta JK. Human brain mechanisms of pain perception and regulation in health and disease. Eur J Pain. 2005;9(4):463-84.
40. Helyes Z, Németh J, Thán M, Bölcskei K, Pintér E, Szolcsányi J. Inhibitory effect of anandamide on resiniferatoxin-induced sensory neuropeptide release in vivo and neuropathic hyperalgesia in the rat. Life Sci. 2003;73(18):2345-53.
41. Herrero JF, Laird JM, López-García JA. Wind-up of spinal cord neurones and pain sensation: much ado about something? Prog Neurobiol. 2000;61(2):169-203.
42. Kumar A, Singh RL, Babu GN. Cell death mechanisms in the early stages of acute glutamate neurotoxicity. Neurosci Res. 2010;66(3):271-8.
43. Hung KL, Wang SJ, Wang YC, Chiang TR, Wang CC. Upregulation of presynaptic proteins and protein kinases associated with enhanced glutamate release from axonal terminals (synaptosomes) of the medial prefrontal cortex in rats with neuropathic pain. Pain. 2014;155(2):377-87.
44. Iasevoli F, Tomasetti C, Buonaguro EF, de Bartolomeis A. The glutamatergic aspects of schizophrenia molecular pathophysiology: role of the postsynaptic density, and implications for treatment. Curr Neuropharmacol. 2014;12(3):219-38.
45. Jernigan CS, Goswami DB, Austin MC, Iyo AH, Chandran A, Stockmeier CA, et al. The mTOR signaling pathway in the prefrontal cortex is compromised in major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2011;35(7):1774-9.
46. Nithianantharajah J, Hannan AJ. Dysregulation of synaptic proteins, dendritic spine abnormalities and pathological plasticity of synapses as experience-dependent mediators of cognitive and psychiatric symptoms in Huntington's disease. Neuroscience. 2013;251:66-74.
47. Wei F, Wang GD, Kerchner GA, Kim SJ, Xu HM, Chen ZF, et al. Genetic enhancement of inflammatory pain by forebrain NR2B overexpression. Nat Neurosci. 2001;4(2):164-9.
48. de Bartolomeis A, Iasevoli F. The Homer family and the signal transduction system at glutamatergic postsynaptic density: potential role in behavior and pharmacotherapy. Psychopharmacol Bull. 2003;37(3):51-83.
49. Errico F, Rossi S, Napolitano F, Catuogno V, Topo E, Fisone G, et al. D-aspartate prevents corticostriatal long-term depression and attenuates schizophrenia-like symptoms induced by amphetamine and MK-801. Neurosci. 2008;28(41):10404-14.
50. Boccella S, Vacca V, Errico F, Marinelli S, Squillace M, Guida F, Di Maio A, Vitucci D, Palazzo E, De Novellis V, Maione S, Pavone F, Usiello A. D-Aspartate modulates nociceptive-specific neuron activity and pain threshold in inflammatory and neuropathic pain condition in mice. Biomed Res Int. 2014. In press.
51. Fagg GE, Matus A. Selective association of N-methyl aspartate and quisqualate types of L-glutamate receptor with brain postsynaptic densities. Proc Natl Acad Sci U S A. 1984;81(21):6876-80.
52. Monahan JB, Michel J. Identification and characterization of an N-methyl-D-aspartate-specific L-[3H]glutamate recognition site in synaptic plasma membranes. J Neurochem. 1987;48(6):1699-708.
53. Hayes DJ, Northoff G. Common brain activations for painful and non-painful aversive stimuli. BMC Neurosci. 2012;13:60.
54. Costa B, Comelli F, Bettoni I, Colleoni M, Giagnoni G. The endogenous fatty acid amide, palmitoylethanolamide, has anti-allodynic and anti-hyperalgesic effects in a murine model of neuropathic pain: involvement of CB(1), TRPV1 and PPARgamma receptors and neurotrophic factors. Pain. 2008;139(3):541-50.
55. Rahn EJ, Guzman-Karlsson MC, David Sweatt J. Cellular, molecular, and epigenetic mechanisms in non-associative conditioning: implications for pain and memory. Neurobiol Learn Mem. 2013;105:133-50.
56. Thomas A, Burant A, Bui N, Graham D, Yuva-Paylor LA, Paylor R. Marble burying reflects a repetitive and perseverative behavior more than novelty-induced anxiety. Psychopharmacology (Berl). 2009;204(2):361-73.
57. Wu LJ, Zhuo M. Targeting the NMDA receptor subunit NR2B for the treatment of neuropathic pain. Neurotherapeutics. 2009;6(4):693-702.
58. Li N, Lee B, Liu RJ, Banasr M, Dwyer JM, Iwata M, et al. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science. 2010;329:959-64.
59. Preskorn SH, Baker B, Kolluri S, Menniti FS, Krams M, Landen JW. An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder. J Clin Psychopharmacol. 2008;28:631-7.
60. Duman RS, Li N, Liu RJ, Duric V, Aghajanian G. Signaling pathways underlying the rapid antidepressant actions of ketamine. Neuropharmacology. 2012;62:35-41.
61. Lo Verme J, La Rana G, Russo R, Calignano A, Piomelli D. The search for the palmitoylethanolamide receptor. Life Sci. 2005;77(14):1685-98.
62. Re G, Barbero R, Miolo A, Di Marzo V. Palmitoylethanolamide, endocannabinoids and related cannabimimetic compounds in protection against tissue inflammation and pain: potential use in companion animals. Vet J. 2007;173(1):21-30.
63. Al-Amin H, Sarkis R, Atweh S, Jabbur S, Saadé N. Chronic dizocilpine or apomorphine and development of neuropathy in two animal models II: effects on brain cytokines and neurotrophins. Exp Neurol. 2011;228(1):30-40.
64. Yalcin I, Barthas F, Barrot M. Emotional consequences of neuropathic pain: insight from preclinical studies. Neurosci Biobehav Rev. 2014;47C:154-64.
65. Almási R, Szoke E, Bölcskei K, Varga A, Riedl Z, Sándor Z, et al. Actions of 3-methyl-N-oleoyldopamine, 4-methyl-N-oleoyldopamine and N-oleoylethanolamide on the rat TRPV1 receptor in vitro and in vivo. Life Sci. 2008;82(11-12):644-51.
66. Maione S, Starowicz K, Cristino L, Guida F, Palazzo E, Luongo L, et al. Functional interaction between TRPV1 and mu-opioid receptors in the descending antinociceptive pathway activates glutamate transmission and induces analgesia. J Neurophysiol. 2009;101(5):2411-22.
67. Ookubo M, Kanai H, Aoki H, Yamada N. Antidepressants and mood stabilizers effects on histone deacetylase expression in C57BL/6 mice: brain region specific changes. J Psychiat Res. 2013;47:1204-14.
68. Takebayashi M, Kagaya A, Inagaki M, Kozuru T, Jitsuiki H, Kutura K, et al. Effects of antidepressants on γ-aminobutyric acid and N-methyl-D-aspartate-induced intracellular Ca2+ concentration increases in primary cultured rat neocortical neurons. Neuropsychobiology. 2000;42:120-6.
69. Nghia NA, Hirasawa T, Kasai H, Obata C, Moriishi K, Mochizuki K, et al. Long-term imipramine treatment increases N-methyl-d-aspartate receptor activity and expression via epigenetic mechanisms. Eur J Pharmacol. 2015;752:69-77.